NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Nanobiotix S.A. (NBTX) Stock Analysis

Nanobiotix S.A. (NBTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NBTX

$25.83

+$1.69 (+7.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NBTX with… →

NBTX Key Statistics

As of Oct 21, 2026
Trading
Open
$25.69
Previous Close
$24.14
Day's Range
25.69–27.50
52-Week Range
14.78–57.14
Volume
165.34K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.59
Valuation
Market Cap
$1.32B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
114.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.27
Financials (FY)
Revenue (FY)
$29.64M
Net Income (FY)
−$23.96M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
50.92M
1-Year Return
+14.19%
Dividend and dates
Avg Volume
148.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NBTX closed at $25.83, +14.19% over 1 year.

Nanobiotix S.A. (NBTX) has a market capitalization of $1.32B.

In fiscal 2025, NBTX reported revenue of $29.64M.

NBTX Stock Return by Calendar Year

Nanobiotix S.A. (NBTX) return since Dec 2020: what $10,000 became

1 year
$10,000 $11,419
+14.19%
5 years
$10,000 $19,808
+98.08%
Since Dec 2020
$10,000 $15,212
+52.12%

If you had invested $10,000 in Nanobiotix S.A. (NBTX) at the close on December 11, 2020, the earliest close on record here, it would have been worth $15,212 at the close on October 21, 2026: +52.12% in total, +7.42% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+11.72%
2025+705.57%
2024−60.58%
2023+98.37%
2022−54.69%
2021−50.91%
2020 (partial year)−2.83%

As of October 21, 2026.

NBTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$29.64M−$23.96M−80.8%
2024−$11.61M−$68.13M586.8%
2023$30.06M−$39.70M−132.1%
2022$0.00−$57.04M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$29.64M—−$10.82M−$23.96M−80.8%
2024−$11.61M—−$68.39M−$68.13M586.8%
2023$30.06M—−$26.78M−$39.70M−132.1%
2022$0.00—−$46.70M−$57.04M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NBTX Valuation vs Biotechnology Median

Median of 608 stocks
MetricNBTXBiotechnology medianvs median
P/S ratio114.3113.308.6x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Nanobiotix S.A. (NBTX) is capitalised at $1.32B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 98.

The most recent close on file for NBTX is $25.83, dated October 21, 2026. That is +$1.69 (+7.00%) against the previous close. The 52-week range on file runs from $14.78 to $57.14. The latest close sits 74.76% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $29.64M. The same year closed with a net loss of $23.96M. Earnings per share on a trailing basis come to −1.27.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $29.64M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 114.31 times revenue. On price-to-sales that is 8.6 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +14.19%. Measured over 5 years, that is +14.65% a year compounded. Beta against the wider market is reported at 0.59. Annualized volatility over the trailing 5 years is 137.33%.

Growth & Income

No dividend is on file for NBTX.

2026 is still running; the total return is +11.72% year to date. Across the complete calendar years on file, 2025 returned +705.57% and 2024 returned −60.58%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Nanobiotix S.A. (NBTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nanobiotix S.A. NBTX $1.32B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Nanobiotix S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Nanobiotix S.A.

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Visit website →